Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404528 | 1.00 | KMT2A (0.51) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL17102000 | 0.83 | KMT2A (0.49) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL27785393 | 0.82 | CTNNB1 (0.46) | KMT2AMEN1ALDH1A1GAAPOLB | |
| SCHEMBL11023514 | 0.80 | KMT2A (0.47) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL2795840 | 0.79 | KMT2A (0.56) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL9545821 | 0.78 | ATM (0.37) | KMT2AMEN1ALDH1A1GAAATM | |
| SCHEMBL6436173 | 0.78 | KMT2A (0.46) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL29472193 | 0.78 | CA1 (0.52) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL9326049 | 0.78 | CASR (0.57) | KMT2AMEN1ALDH1A1GAACA1 | |
| SCHEMBL2951312 | 0.78 | CA1 (0.52) | KMT2AMEN1ALDH1A1GAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| CN-115108901-A | Synthetic method of alpha-hydroxycarboxylic acid compound | 四川大学 | 2022-09-27 | — | — | CN | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
| US-20110287059-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2011-11-24 | — | — | US | disclosed |
| EP-2367444-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368111-A1 | HONEY ANALYSIS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010082845-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010082846-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | FABP6, NNT, IAPP | KMT2A 3315/4885MEN1 276/4885ALDH1A1 2943/4885 |
| US-20110287059-A1 | HONEY ANALYSIS | GLO1, GLMN, AGER | KMT2A 1146/4885MEN1 1512/4885ALDH1A1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.